| Autor: |
Jakobsson M; Pfizer AB, 113 63 Stockholm, Sweden., Strambi A; Fondazione Toscana Life Sciences, 53100 Siena, Italy., Nilsson F; Pfizer AB, 113 63 Stockholm, Sweden., Arpegård J; Pfizer AB, 113 63 Stockholm, Sweden., Dalén J; ICON plc, 111 22 Stockholm, Sweden. |
| Jazyk: |
angličtina |
| Zdroj: |
Future oncology (London, England) [Future Oncol] 2024; Vol. 20 (20), pp. 1385-1392. Date of Electronic Publication: 2024 Jul 26. |
| DOI: |
10.1080/14796694.2024.2351352 |
| Abstrakt: |
Aim: Assess the time-to-treatment discontinuation (TTD) and overall survival (OS) in a Swedish metastatic renal cell carcinoma (mRCC) nationwide cohort who received second-line axitinib. Methods: Retrospective analysis of 110 patients with mRCC treated with second-line axitinib in Sweden (2012-2019). Patients included in the study received axitinib after mainly first-line sunitinib or pazopanib. Results: The median (95% CI) TTD of patients who received second-line axitinib was 5.2 (3.7-6.1) months with 6 (5.5%) patients still receiving treatment at the time of analysis. Median (95% CI) OS was 12.2 (7.7-14.2) months. Conclusion: The results are consistent with previous findings in mRCC and add to the evidence demonstrating efficacy of second-line axitinib, after failure of a prior anti-angiogenic therapy in a real-world setting. Clinical Trial Registration: NCT04669366 (ClinicalTrials.gov). |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
